DEL-1 restrains osteoclastogenesis and inhibits inflammatory bone loss in nonhuman primates

See allHide authors and affiliations

Science Translational Medicine  30 Sep 2015:
Vol. 7, Issue 307, pp. 307ra155
DOI: 10.1126/scitranslmed.aac5380

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

DELivering new therapies for chronic inflammation

Chronic inflammation is prevalent in nearly half of adult teeth and gums in the U.S. population, and this so-called periodontitis can increase a patient’s risk of developing other inflammatory diseases in the heart (atherosclerosis) and joints (rheumatoid arthritis). Shin et al. capitalized on the natural anti-inflammatory activity of the protein DEL-1, finding that it not only blocked excessive immune cell infiltration into the periodontium but also had innate anti-osteoclastogenic activity; that is, it stopped bone loss by interrupting the signaling pathways to osteoclasts, the bone-resorbing cells. In vitro, in human and mice osteoclast precursor cells, DEL-1 prevented osteoclast differentiation by inhibiting NFATc1 activity. In vivo, in mouse and nonhuman primate models of periodontitis, giving DEL-1 locally reduced inflammation and tissue destruction, thus halting any tissue loss. The mechanism appears to be two-pronged: working “upstream” in disease signaling pathways to prevent inflammatory cell recruitment to the teeth and gums, as well as acting “downstream” to stop osteoclastogenesis. With data in a monkey model that represents the human disease, anatomy, and immune system closely, it is likely that DEL-1–based therapeutics could translate soon once safety of this endogenous molecule is confirmed.


DEL-1 (developmental endothelial locus–1) is an endothelial cell–secreted protein that regulates LFA-1 (lymphocyte function–associated antigen–1) integrin–dependent leukocyte recruitment and inflammation in various tissues. We identified a novel regulatory mechanism of DEL-1 in osteoclast biology. Specifically, we showed that DEL-1 is expressed by human and mouse osteoclasts and regulates their differentiation and resorptive function. Mechanistically, DEL-1 inhibited the expression of NFATc1, a master regulator of osteoclastogenesis, in a Mac-1 integrin–dependent manner. In vivo mechanistic analysis has dissociated the anti-inflammatory from the anti–bone-resorptive action of DEL-1 and identified structural components thereof mediating these distinct functions. Locally administered human DEL-1 blocked inflammatory periodontal bone loss in nonhuman primates—a relevant model of human periodontitis. The ability of DEL-1 to regulate both upstream (inflammatory cell recruitment) and downstream (osteoclastogenesis) events that lead to inflammatory bone loss paves the way to a new class of endogenous therapeutics for treating periodontitis and perhaps other inflammatory disorders.

View Full Text